Clinical scenarios-based guide for tofacitinib in rheumatoid arthritis

Abstract

Tofacitinib was the first Janus kinase inhibitor to be approved for the treatment of rheumatoid arthritis (RA), and there is a large body of data to inform the efficacy and safety of this drug for patients at different places in their treatment journeys and with diverse demographics and characteristics. Here, we summarize tofacitinib clinical efficacy and safety data from some clinical trials, post hoc analyses, and real-world studies, which provide evidence of the efficacy of tofacitinib in treating patients with RA at various stages of their treatment journeys, and with differentiating baseline characteristics, such as age, gender, race, and body mass index. In addition, we review the safety data available from different patient subpopulations in the tofacitinib clinical development program, real-world data, and findings from the ORAL Surveillance post-marketing safety study that included patients aged ⩾50 years with pre-existing cardiovascular risk factors. The available efficacy and safety data in these subpopulations can enable better discussions between clinicians and patients to guide informed decision-making and individualized patient care.

Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a post hoc analysis of ORAL Surveillance

“…It should be noted that at least ~30% of patients had MDA/HDA throughout the duration of study, suggesting that the relationship between disease activity and AE risk may have been observed due to patients not attaining the treatment target; this is despite the likelihood of patients exhibiting improvements from baseline in CDAI with tofacitinib or TNFi treatment. 32 …”

Tofaticinib as a potential therapeutic agent: a review

“…Several research investigations are underway to investigate the potential of tofacitinib in treatment of other indications. 30 Effectiveness and safety of tofacitinib for treatment of psoriasis is under phase III investigation. 30 Potential efficacy of tofacitinib therapy for the treatment of alopecia areata is in phase II clinical trial.…”

“…30 Effectiveness and safety of tofacitinib for treatment of psoriasis is under phase III investigation. 30 Potential efficacy of tofacitinib therapy for the treatment of alopecia areata is in phase II clinical trial. 5,30 Tofacitinib efficiency in treating ankylosing spondylitis is also under phase III clinical trial investigation.…”

“…30 Potential efficacy of tofacitinib therapy for the treatment of alopecia areata is in phase II clinical trial. 5,30 Tofacitinib efficiency in treating ankylosing spondylitis is also under phase III clinical trial investigation. There are published reports demonstrating the therapeutic efficiency of tofacitinib therapy in treatment of vitiligo and atopic dermatitis.…”

“…There are published reports demonstrating the therapeutic efficiency of tofacitinib therapy in treatment of vitiligo and atopic dermatitis. [5][6][7][8][9][10][11][12][13][14]30…”